VIDEO: Fosgonimeton alone improved cognition in study

SAN DIEGO – Athira Pharma’s first intervention trial involving fosgonimeton showed that use of the drug alone showed a “sizable effect” in cognitive improvement at 26 weeks, according to chief medical officer Hans Moebius, MD, PhD.

“We also see a statistically significant benefit on neurofilament light levels,” Moebius said at the Alzheimer’s Association International Conference.

Moebius said the data indicate an “unexpected drug interaction,” because only the fosgonimeton-alone group showed “a sizable effect on ADAS-Cog11 [a measure of cognition] and also on the P300 latency.”